Table 1. Characteristics of Case Patients With Hepatitis B Flare and Matched Control Patients Among a Cohort of Individuals Carrying Hepatitis B Virus in Taiwan.
| Characteristic | No. (%) | |
|---|---|---|
| Case patients (n = 66 702) | Matched control patients (n = 666 989) | |
| Age, mean (SD), y | 50.18 (13.83) | 50.18 (13.83) |
| Men | 47 492 (71.20) | 474 903 (71.20) |
| Women | 19 210 (28.80) | 192 086 (28.80) |
| Bcr-Abl TKI used before index datea | ||
| 60 d | 58 (0.09) | 161 (0.02) |
| 90 d | 64 (0.10) | 165 (0.02) |
| 180 d | 69 (0.10) | 172 (0.03) |
| 365 d | 73 (0.11) | 180 (0.03) |
| Cancer history 6 mo prior to the index date | ||
| Chronic myeloid leukemia and monocytic leukemiab | 26 (0.04) | 106 (0.02) |
| Acute leukemia | ||
| Myeloid | 85 (0.13) | 175 (0.03) |
| Lymphoid | 79 (0.12) | 138 (0.02) |
| Soft-tissue tumor | 1022 (1.53) | 2944 (0.44) |
| Other cancer | 18 121 (27.17) | 50 628 (7.59) |
| No diagnosis | 47 369 (71.02) | 612 998 (91.91) |
| Other comorbidities | ||
| Cirrhosis and other liver diseasec | 1152 (1.73) | 3516 (0.53) |
| Transplantation for hematologic malignant neoplasmsd | 34 (0.05) | 63 (0.01) |
| Medications as a known risk factor hepatitis B flare | ||
| Immunosuppressantse | 4172 (6.25) | 16 031 (2.40) |
| Cytotoxic chemotherapyf | 1844 (2.76) | 4347 (0.65) |
| Rituximab | 89 (0.13) | 181 (0.03) |
Abbreviation: TKI, tyrosine kinase inhibitor.
The number of case and control patients receiving Bcr-Abl TKIs at 120 days was too close to its adjacent category; therefore, the data could not be released.
Number of cases of monocystic leukemia was smaller than the threshold for data release; therefore, the number of cases of monocystic leukemia was combined with those of chronic myeloid leukemia.
Alcohol cirrhosis, biliary cirrhosis, or alcoholic liver disease.
Transplantation included allogenic or autologous. Transplantation history was assessed 1 year prior to the index date, and at least 1 or more record of transplantation was regarded as having transplantation history.
Immunosuppressants include systemic steroids (prednisolone, methylprednisolone, dexamethasone, hydrocortisone) and other immunosuppressants (everolimus, sirolimus, tacrolimus, azathioprine, cyclosporin, mycophenolate). Use 180 days prior to index date with cumulative use of at least 28 days was classified as immunosuppressant users.
Cytotoxic chemotherapy included 5-fluorouracil, gemcitabine, capecitabine, methotrexate, oxaliplatin, carboplatin, cyclophosphamide, doxorubicin, epirubicin, irinotecan, etoposide, paclitaxel, docetaxel, vinorelbine, cytarabine, daunorubicin, idarubicin, or other record of having chemotherapy in the clinics.